https://www.selleckchem.com/Androgen-Receptor.html
0%, 9.0%, and 9.3%, p = 0.74), while cardiovascular death decreased over time (5.7%, 5.1%, and 4.8%, p = 0.03). The adjusted risk for all-cause death and for cardiovascular death progressively decreased from Cohort-1 to Cohort-2 (HR0.89, 95%CI0.80 to 0.99, p = 0.03, and HR0.80, 95%CI0.70 to 0.92, p = 0.002, respectively), and from Cohort-2 to Cohort-3 (HR0.86, 95%CI0.78 to 0.95, p = 0.004, and HR0.77, 95%CI0.67-0.89, p less then 0.001, respectively). The risks for stroke and repeated coronary revascularization also improved over time.
Like
Comment
Share
